Advancing periodontal care with novel light therapy
A novel light therapy could help patients manage periodontitis at home.
An ongoing investigation known as the LumoKaunas2023 study was recently highlighted in the British Dental Journal. Researchers are evaluating the efficacy of a light-activated antibacterial therapy in patients with chronic stage III to IV periodontitis. As of December 2024, 38 of the 60 participants have been enrolled in the study; the LumosKaunas 2023 study is expected to conclude by early autumn 2025.
The therapy works by combining a specialized mouthwash with light therapy to reduce periodontitis-associated inflammation. Previous studies have demonstrated that the novel light therapy could successfully treat early-stage periodontitis. For instance, the therapy provided a healing rate of about 54% on the basis of bleeding on probing measures compared with just 22% among those who didn’t receive the therapy.
The researchers suggested that the novel light therapy could offer an alternative to conventional periodontal therapy options as well as help at-risk patients enhance their oral health and minimize the severity of infections.
Read more: British Dental Journal
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.